Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany.
World J Urol. 2011 Apr;29(2):149-55. doi: 10.1007/s00345-011-0655-6. Epub 2011 Feb 19.
Combination therapy of male lower urinary tract symptoms with α(1)-adrenoceptor and muscarinic receptor antagonists attracts increasing interest. Propiverine is a muscarinic receptor antagonist possessing additional properties, i.e., block of L-type Ca(2+) channels. Here, we have investigated whether propiverine and its metabolites can additionally antagonize α(1)-adrenoceptors.
Human prostate and porcine trigone muscle strips were used to explore inhibition of α(1)-adrenoceptor-mediated contractile responses. Chinese hamster ovary (CHO) cells expressing cloned human α(1)-adrenoceptors were used to determine direct interactions with the receptor in radioligand binding and intracellular Ca(2+) elevation assays.
Propiverine concentration-dependently reversed contraction of human prostate pre-contracted with 10 μM phenylephrine (-log IC(50) [M] 4.43 ± 0.08). Similar inhibition was observed in porcine trigone (-log IC(50) 5.01 ± 0.05), and in additional experiments consisted mainly of reduced maximum phenylephrine responses. At concentrations ≥1 μM, the propiverine metabolite M-14 also relaxed phenylephrine pre-contracted trigone strips, whereas metabolites M-5 and M-6 were ineffective. In radioligand binding experiments, propiverine and M-14 exhibited similar affinity for the three α(1)-adrenoceptor subtypes with -log K (i) [M] values ranging from 4.72 to 4.94, whereas the M-5 and M-6 did not affect [(3)H]-prazosin binding. In CHO cells, propiverine inhibited α(1)-adrenoceptor-mediated Ca(2+) elevations with similar potency as radioligand binding, again mainly by reducing maximum responses.
In contrast to other muscarinic receptor antagonists, propiverine exerts additional L-type Ca(2+)-channel blocking and α(1)-adrenoceptor antagonist effects. It remains to be determined clinically, how these additional properties contribute to the clinical effects of propiverine, particularly in male voiding dysfunction.
α(1)-肾上腺素能受体和毒蕈碱受体拮抗剂联合治疗男性下尿路症状引起了越来越多的关注。丙哌维林是一种具有附加特性的毒蕈碱受体拮抗剂,即阻断 L 型钙(2+)通道。在这里,我们研究了丙哌维林及其代谢物是否还可以拮抗 α(1)-肾上腺素能受体。
使用人前列腺和猪三角肌条来探索抑制 α(1)-肾上腺素能受体介导的收缩反应。使用表达克隆人 α(1)-肾上腺素受体的中国仓鼠卵巢(CHO)细胞来确定在放射性配体结合和细胞内 Ca(2+)升高测定中与受体的直接相互作用。
丙哌维林浓度依赖性地逆转了 10 μM 苯肾上腺素预收缩的人前列腺的收缩(-log IC(50)[M]为 4.43 ± 0.08)。在猪三角肌中也观察到类似的抑制(-log IC(50)为 5.01 ± 0.05),并且在其他实验中主要由减少的最大苯肾上腺素反应组成。在浓度≥1 μM 时,丙哌维林的代谢物 M-14 也使苯肾上腺素预收缩的三角肌条松弛,而代谢物 M-5 和 M-6 则无效。在放射性配体结合实验中,丙哌维林和 M-14 对三种 α(1)-肾上腺素能受体亚型具有相似的亲和力,-log K(i)[M]值范围为 4.72 至 4.94,而 M-5 和 M-6 则不影响[3H]-哌唑嗪结合。在 CHO 细胞中,丙哌维林抑制 α(1)-肾上腺素能受体介导的 Ca(2+)升高的作用与放射性配体结合相似,再次主要通过减少最大反应。
与其他毒蕈碱受体拮抗剂不同,丙哌维林具有附加的 L 型钙(2+)通道阻断和 α(1)-肾上腺素能受体拮抗剂作用。在临床上,这些附加特性如何有助于丙哌维林的临床效果,特别是在男性排尿功能障碍方面,仍有待确定。